p-value | Hazard ratio (95% CI) | |
Treatment duration | 0.670 | 1.01 (0.95–1.08) |
Age at treatment initiation | 0.361 | 0.98 (0.94–1.02) |
Female | 0.875 | 0.94 (0.45–1.98) |
Non-Caucasian | 0.090# | 2.03 (0.90–4.60) |
Extrapulmonary involvement | 0.964 | 1.03 (0.36–2.96 |
Biomarkers at start of therapy | ||
SUVmax | ||
Total | 0.033# | 1.10 (1.00–1.20) |
Lungs | 0.703 | 1.02 (0.93–1.11) |
Mediastinum | 0.001# | 1.16 (1.06–1.26) |
ACE | 0.925 | 1.00 (0.99–1.01) |
CRP | 0.712 | 1.17 (0.52–2.63) |
sIL-2R | 0.103# | 1.00 (1.00–1.00) |
VC % | 0.410 | 0.99 (0.97–1.01) |
FVC % | 0.367 | 0.99 (0.97–1.01) |
FEV1 % | 0.648 | 1.00 (0.98–1.02) |
Tiffeneau index | 0.967 | 1.00 (0.97–1.03) |
DLCO % | 0.255 | 0.99 (0.96–1.01) |
Biomarkers after 6 months of treatment | ||
SUVmax | ||
Total | 0.312 | 1.12 (0.90–1.41) |
Lungs | 0.758 | 1.08 (0.66–1.78) |
Mediastinum | 0.226 | 1.14 (0.92–1.41) |
ACE | 0.816 | 1.00 (0.99–1.02) |
CRP | 0.637 | 1.25 (0.50–3.09) |
sIL-2R | 0.957 | 1.00 (1.00–1.00) |
Leukocytes | 0.941 | 0.99 (0.84–1.12) |
Biomarkers at end of therapy | ||
ACE | 0.917 | 1.00 (0.98–1.02) |
CRP | 0.343 | 1.50 (0.65–3.43) |
sIL-2R | 0.841 | 1.00 (1.00–1.00) |
Leukocytes | 0.750 | 1.03 (0.86–1.24) |
VC % | 0.406 | 0.99 (0.96–1.01) |
FEV1 % | 0.839 | 1.00 (0.98–1.02) |
Tiffeneau index | 0.762 | 1.01 (0.98–1.04) |
DLCO % | 0.542 | 0.99 (0.97–1.02) |
Change in biomarkers | ||
ACE % | 0.671 | 0.67 (0.99–1.00) |
sIL-2R % | 0.374 | 1.00 (0.99–1.00) |
VC % | 0.815 | 1.00 (0.95–1.04) |
FEV1 % | 0.649 | 1.01 (0.97–1.05) |
SUVmax: maximum standardised uptake value; ACE: angiotensin-converting enzyme; CRP: C-reactive protein; sIL-2R: soluble interleukin-2 receptor; VC: vital capacity; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; DLCO: diffusion capacity of the lung for carbon monoxide. #: all factors having p<0.2 were selected for further analysis in multivariate analysis.